Inovio Pharmaceuticals Inc. [INO] Is Currently 6.02 above its 200 Period Moving Avg: What Does This Mean?

Inovio Pharmaceuticals Inc. [NASDAQ: INO] surged by $0.1 during the normal trading session on Tuesday and reaching a high of $1.79 during the day while it closed the day at $1.76. The company report on September 1, 2022 that INOVIO Reports Inducement Grants Under Inducement Plan.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from infectious diseases, cancer, and diseases associated with HPV, today announced that it has made equity grants to two newly hired employees, including a Vice President of Clinical Development, under its 2022 Inducement Plan (the “Inducement Plan”).

On August 31, 2022 (the “Grant Date”), the Compensation Committee of INOVIO’s Board of Directors approved the award of restricted stock units (“RSUs”) covering an aggregate of 5,000 shares of common stock and options to purchase an aggregate of 26,250 shares of common stock to two newly hired employees in accordance with Nasdaq Listing Rule 5635(c)(4).

Inovio Pharmaceuticals Inc. stock has also loss -5.88% of its value over the past 7 days. However, INO stock has declined by -3.30% in the 3 months of the year. Over the past six months meanwhile, it has lost -50.70% and lost -64.73% year-on date.

The market cap for INO stock reached $454.31 million, with 249.40 million shares outstanding and 245.50 million shares in the current float. Compared to the average trading volume of 5.83M shares, INO reached a trading volume of 5958610 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Inovio Pharmaceuticals Inc. [INO]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for INO shares is $4.20 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on INO stock is a recommendation set at 2.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

RBC Capital Mkts have made an estimate for Inovio Pharmaceuticals Inc. shares, keeping their opinion on the stock as Sector Perform, with their previous recommendation back on July 19, 2022. The new note on the price target was released on May 11, 2022, representing the official price target for Inovio Pharmaceuticals Inc. stock. Previously, the target price had yet another raise from $8 to $10, while BofA Securities kept a Neutral rating on INO stock. On December 29, 2021, analysts decreased their price target for INO shares from 8 to 6.

The Average True Range (ATR) for Inovio Pharmaceuticals Inc. is set at 0.15, with the Price to Sales ratio for INO stock in the period of the last 12 months amounting to 216.34. The Price to Book ratio for the last quarter was 1.39, with the Price to Cash per share for the same quarter was set at 1.35.

INO stock trade performance evaluation

Inovio Pharmaceuticals Inc. [INO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -5.88. With this latest performance, INO shares dropped by -23.14% in over the last four-week period, additionally sinking by -50.70% over the last 6 months – not to mention a drop of -77.35% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for INO stock in for the last two-week period is set at 38.45, with the RSI for the last a single of trading hit 36.05, and the three-weeks RSI is set at 41.21 for Inovio Pharmaceuticals Inc. [INO]. The present Moving Average for the last 50 days of trading for this stock 2.1821, while it was recorded at 1.7420 for the last single week of trading, and 2.9859 for the last 200 days.

Inovio Pharmaceuticals Inc. [INO]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Inovio Pharmaceuticals Inc. [INO] shares currently have an operating margin of -17535.79 and a Gross Margin at -166.56. Inovio Pharmaceuticals Inc.’s Net Margin is presently recorded at -17109.87.

Return on Equity for this stock declined to -70.55, with Return on Assets sitting at -58.26.

Inovio Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.20 and a Current Ratio set at 3.20.

Earnings per share (EPS) analysis for Inovio Pharmaceuticals Inc. [INO] stock

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for INO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Inovio Pharmaceuticals Inc. go to 45.80%.

Inovio Pharmaceuticals Inc. [INO]: Insider Ownership positions

There are presently around $200 million, or 46.20% of INO stock, in the hands of institutional investors. The top three institutional holders of INO stocks are: STATE STREET CORP with ownership of 32,195,674, which is approximately 38.369% of the company’s market cap and around 0.50% of the total institutional ownership; BLACKROCK INC., holding 19,925,606 shares of the stock with an approximate value of $35.07 million in INO stocks shares; and VANGUARD GROUP INC, currently with $23.53 million in INO stock with ownership of nearly 18.881% of the company’s market capitalization.

Positions in Inovio Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 93 institutional holders increased their position in Inovio Pharmaceuticals Inc. [NASDAQ:INO] by around 25,691,185 shares. Additionally, 72 investors decreased positions by around 4,055,531 shares, while 57 investors held positions by with 83,789,941 shares. The mentioned changes placed institutional holdings at 113,536,657 shares, according to the latest SEC report filing. INO stock had 21 new institutional investments in for a total of 351,324 shares, while 35 institutional investors sold positions of 872,274 shares during the same period.


Please enter your comment!
Please enter your name here